Please assess the completion status of the following clinical trial:

Trial Title: A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.~* Participants must have a pathologic diagnosis of classical Hodgkin lymphoma (cHL) who are relapsed or refractory with one of the following:.~  i) Autologous stem cell transplant (ASCT) ineligible patients.~ii) Patients after failure of ASCT.~- Must have at least one lesion that is \> 15 mm (1.5 cm) in the longest diameter and avid by Fluoro Deoxy Glucose (FDG) Positron Emission Tomography (PET) scan.~Exclusion Criteria~* Known central nervous system lymphoma.~* Participants with nodular lymphocyte-predominant Hodgkin lymphoma (HL).~* Participants with known history of pancreatitis or progressive multifocal leukoencephalopathy (PML).~* Other protocol-defined Inclusion/Exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Module A (Type: EXPERIMENTAL): Nivolumab combined with Brentuximab
- Module B (Type: EXPERIMENTAL): Brentuximab alone

Based on this trial design, predict the completion outcome and termination type (if applicable).